In Brief: U.S. Surgical
This article was originally published in The Gray Sheet
Executive Summary
U.S. Surgical: Maintains in Oct. 14 comments to FDA that it has legal authority to seek rejection of Sofamor Danek's premarket approval application for its Novus LC threaded interbody fusion system. USSC petitioned FDA in July to turn down the Novus PMA because it lacks two-year follow-up data, and Sofamor Danek responded by claiming that USSC could not participate in the review process and that FDA did not have a two-year rule ("The Gray Sheet" Aug. 11, I&W-3). FDA has "created a de facto policy requiring such data" and has "consistently enforced this policy over the years with respect to orthopedic implantable devices," USSC maintains...
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.